Showing 1-10 of 16 grants
Title | Institution | Researcher | Program | Duration | Total Award Amount |
---|---|---|---|---|---|
Understanding Disease Mechanisms Underlying Type 1 Diabetes | Baylor College of Medicine | Ashok Balasubramanyam | Cures | 01-November-2024 to 31-October-2027 | $967,091.04 |
Unraveling the Influence of Obesity on Progression Along Preclinical Stages of Type 1 Diabetes | Baylor College of Medicine | Maria Redondo | Cures | 01-June-2025 to 31-May-2028 | $1,124,188.00 |
A novel approach to overcome innate immunity in beta-cell replacement therapy for type 1 diabetes | Baylor Research Institute | Bashoo Naziruddin | Cures | 01-January-2025 to 31-December-2027 | $749,769.68 |
Investigation of novel local immunomodulating strategies to enhance islet transplantation for T1D | The Methodist Hospital Research Institute | Alessandro Grattoni | Cures | 01-July-2022 to 30-June-2026 | $962,995.99 |
Prevascularized encapsulation platform with local immunosuppression for Islet transplantation | The Methodist Hospital Research Institute | Alessandro Grattoni | Cures | 01-August-2021 to 31-January-2026 | $660,000.00 |
Tolerance inducing NanoLymph for in vivo generation of islet autoantigen-specific regulatory T cells | The Methodist Hospital Research Institute | Ying Xuan Chua | Cures | 01-April-2025 to 31-March-2026 | $200,000.00 |
GABP regulation of human beta cell proliferation | The University of Texas Health Science Center at Houston | Richard Cox | Cures | 01-September-2024 to 31-August-2026 | $200,000.00 |
MRI of Pancreas Perfusion in Response to Glucose | University of Texas at Austin | Jack Virostko | Cures | 01-July-2023 to 30-June-2025 | $187,620.00 |
Can Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Mitigate Diabetic Ketoacidosis Risk? | University of Texas Health Science Center at San Antonio | Muhammad Abdul-Ghani | Improving Lives | 01-June-2019 to 30-September-2025 | $1,573,835.31 |
Immune-checkpoint engineered beta cells as treatment for T1D | UT Southwestern | Andrew Wang | Cures | 01-October-2023 to 30-September-2026 | $746,818.40 |